Joint fluid in 62% of patients with inflammatory arthritis of unknown cause tested positive for DNA of Chlamydia pneumoniae (typically starts as respiratory infection) and/or Chlamydia trachomatis (typically starts as genito-urinary infection). It appears that new cases of Chlamydia related arthritis likely far outnumber new rheumatoid arthritis cases each year in the U.S.
Background: Spondylarthritis (SpA) represents a group of arthritidies that share clinical features such as inflammatory back pain and inflammation at sites where tendons attach to bone. (“Arthritidies” means arthritis types – there are more than 100, and someone can have more than one.) The SPA group includes:
• Ankylosing spondylitis (AS) – arthritis of the spine where vertebrae grow together/become stiff, and form bony outgrowths.
• Psoriatic arthritis – associated with psoriasis, can affect spine & any other part of body.
• Inflammatory bowel-disease-related arthritis, affects about 25% of IBD patients, often long before onset of IBD; often affects spine
• Reactive arthritis (ReA) – arthritis usually causing painful & swollen joints – but triggered by an infection in another part of body.
• Undifferentiated spondylarthritides (uSpA) – arthritis of spine/sacroiliac, etiology unknown; remains to be classified or differentiated, and if triggered by an infection becomes classified as ReA.
Since Chlamydia trachomatis or Chlamydia pneumoniae (which are often asymptomatic) frequently cause reactive arthritis (ReA), a new study examined whether there was a connection between these two infections and uSpA. The study was published in the May issue of Arthritis & Rheumatism.*
Subscribe to the World's Most Popular Newsletter (it's free!)
Led by John D. Carter, MD, of the University of South Florida, the study involved blood and synovial tissue analysis from 26 patients who had chronic uSpA or Chlamydia-induced ReA. Synovial tissue samples from 167 osteoarthritis patients were used as controls. Samples were analyzed to assess chlamydial DNA and the 26 subjects were asked if they had any known exposure to Chlamydia trachomatis or Chlamydia pneumoniae and if so, the infection was documented in relation to the onset of their uSpA.
They also underwent a physical exam that included evaluation of swollen and tender joints and other symptoms of SpA. The results showed that the rate of Chlamydia infection was 62 percent in uSpA patients, significantly higher than the 12 percent seen in control subjects.
It is believed that as many as 150,000 cases of Chlamydia trachomatis-induced ReA may appear in the U.S. each year compared to about 125,000 new cases of rheumatoid arthritis.
This is a low estimate since it does not include cases resulting from Chlamydia pneumoniae.
“Thus, Chlamydia-induced ReA represents a considerable burden on the health care systems of the U.S. and other nations, and its impact on those systems may well be significantly underrecognized,” the authors state.
Most women with genital Chlamydia trachomatis infection have no symptoms at the time of the initial infection; this was also true of the patients in the study who had DNA evidence of Chlamydia. For Chlamydia pneumoniae, as many as 70 percent of acute infections are asymptomatic and, even when there are symptoms, definitive identification of the organism is rare. The authors point out that relying on identification of a symptomatic infection may therefore result in routine underdiagnosis or misdiagnosis of Chlamydia-induced ReA.
They add that because ReA is a type of SpA and patients with ReA do not present with the classic combination of symptoms of arthritis, conjunctivitis/iritis and urethritis, it is reasonable to believe that Chlamydia trachomatis plays a role in causing uSpA – which in that case would be ReA.
They conclude that although there is no diagnostic test for Chlamydia-induced ReA, testing for chlamydial DNA in the synovial tissue of patients thought to have ReA may be the most accurate way of diagnosing the condition.
* Article: “Chlamydiae as Etiologic Agents in Chronic Undifferentiated Spondylarthritis,” Carter JD, et al., Arthritis & Rheumatism, May 2009.
Source: Wily Blackwell, publisher of Arthritis & Rheumatism journal, press release Apr 30, 2009
ME/CFS/FM, see also: “Chlamydia pneumoniae in chronic fatigue syndrome and fibromyalgia,” by James Kepner, founder of CpnHelp.org, a website devoted to the understanding and treatment of Chlamydia pneumoniae, an infectious bacteria implicated in a number of human illnesses.”